Anixa Biosciences (ANIX) Stock
Clinical stage biotech developing immunotherapies and diagnostic tests. Here's the price, business snapshot, and what's worth knowing about Anixa Biosciences in November 2026.
Anixa Biosciences, Inc. (ANIX) is a small-cap, clinical-stage biotechnology company focused on developing immunotherapies and diagnostic technologies. Investors should know it operates in a high-risk, high-reward segment: progress depends heavily on clinical trial outcomes, regulatory decisions and successful commercialisation of any products. With a market capitalisation of about $137.6m, liquidity and analyst coverage may be limited, which can increase share-price volatility. Key potential value drivers include trial readouts, regulatory milestones, strategic partnerships and diagnostic adoption; conversely, setbacks, funding needs and dilution are common risks for companies at this stage. For those tracking ANIX, review company filings, press releases, clinicaltrials.gov entries and quarterly cash-flow reports to gauge runway and progress. This summary is for general education only, not personalised investment advice. Consider your risk tolerance and diversification needs, and consult a financial professional before making investment decisions.
Anixa Biosciences (ANIX) Stock Forecast
Analyst price target, next 12 months
$7.33
+145.3% vs today's $2.99
Price range over the last 12 months
In the middle of its 12-month range
Analysts covering Anixa Biosciences have a consensus 12-month target of $7.33, above the current price of $2.99.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 25 May 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts strongly recommend buying Anixa Biosciences stock, expecting its price to rise significantly.
Financial Health
Anixa Biosciences has stable cash flow and book value, indicating reasonable financial stability.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Pipeline Catalysts
Trial readouts and regulatory milestones can materially affect valuation — though outcomes are uncertain and setbacks are common.
Technology Focus
Focus on immunotherapies and diagnostics may offer long-term opportunities if programmes succeed, but development and commercial risks remain significant.
Market Dynamics
As a small-cap biotech with ~ $137.6m market cap, ANIX can be volatile and may face liquidity or funding challenges; diversification helps manage risk.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
